跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ROPIVACAINE-AFT SOLUTION FOR INFUSION 0.2% W/V - HSA Drug Approval Details
Approvals
/
HSA
/
ROPIVACAINE-AFT SOLUTION FOR INFUSION 0.2% W/V
Approved
THERAPEUTIC
ROPIVACAINE-AFT SOLUTION FOR INFUSION 0.2% W/V
ELPEN PHARMACEUTICAL CO., INC (GREECE)
🇸🇬 Health Sciences Authority
Approval Date
Jun 8, 2017
Approval ID
0e3fc520acf48e56
Company
ELPEN PHARMACEUTICAL CO., INC (GREECE)
Type
Therapeutic
Approval Details
Approval Id
0e3fc520acf48e56
Drug Name
ROPIVACAINE-AFT SOLUTION FOR INFUSION 0.2% W/V
Product Name
ROPIVACAINE-AFT SOLUTION FOR INFUSION 0.2% W/V
Approval Number
SIN15264P
Approval Date
2017-06-08
Registrant
APEX PHARMA MARKETING PTE. LTD.
Licence Holder
APEX PHARMA MARKETING PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
PRESCRIPTION ONLY MEDICINES
Dosage Form
INFUSION, SOLUTION
Route Of Administration
EPIDURAL
Atc Code
N01BB09
Atc Item Name
ropivacaine
Pharma Manufacturer Name
APEX PHARMA MARKETING PTE. LTD.
Active Ingredients
Ropivacaine base 1.76 mg/mL eqv Ropivacaine hydrochloride
2.0 mg/mL
ROPIVACAINE BASE 1.76 MG/ML EQV ROPIVACAINE HYDROCHLORIDE
2 MG/ML
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Jun 8, 2017
Approval ID
0e3fc520acf48e56
Type
Therapeutic
Back to HSA Approvals
